HighTower Advisors LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,005 shares of the company’s stock after purchasing an additional 2,813 shares during the period. HighTower Advisors LLC’s holdings in Zoetis were worth $11,809,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. People s United Financial Inc. lifted its holdings in shares of Zoetis by 21.6% in the 2nd quarter. People s United Financial Inc. now owns 16,230 shares of the company’s stock valued at $1,012,000 after acquiring an additional 2,888 shares during the last quarter. First Allied Advisory Services Inc. lifted its holdings in shares of Zoetis by 21.5% in the 2nd quarter. First Allied Advisory Services Inc. now owns 9,533 shares of the company’s stock valued at $590,000 after acquiring an additional 1,687 shares during the last quarter. Sandhill Capital Partners LLC lifted its holdings in shares of Zoetis by 0.9% in the 2nd quarter. Sandhill Capital Partners LLC now owns 341,204 shares of the company’s stock valued at $21,284,000 after acquiring an additional 2,974 shares during the last quarter. Balyasny Asset Management LLC lifted its holdings in shares of Zoetis by 55.5% in the 2nd quarter. Balyasny Asset Management LLC now owns 44,330 shares of the company’s stock valued at $2,765,000 after acquiring an additional 15,830 shares during the last quarter. Finally, Aureus Asset Management LLC lifted its holdings in shares of Zoetis by 1.6% in the 2nd quarter. Aureus Asset Management LLC now owns 236,281 shares of the company’s stock valued at $14,739,000 after acquiring an additional 3,730 shares during the last quarter. Hedge funds and other institutional investors own 93.20% of the company’s stock.

Shares of Zoetis Inc. (ZTS) traded up 0.69% during mid-day trading on Friday, reaching $63.76. 1,981,436 shares of the company’s stock traded hands. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $65.83. The company’s 50-day moving average price is $62.44 and its 200-day moving average price is $59.64. The stock has a market capitalization of $31.19 billion, a PE ratio of 36.04 and a beta of 1.02.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the prior year, the company posted $0.49 EPS. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current year.

A number of brokerages recently commented on ZTS. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Tuesday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 price target (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. Zoetis presently has an average rating of “Buy” and an average price target of $65.76.

WARNING: “Zoetis Inc. (ZTS) Shares Bought by HighTower Advisors LLC” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/30/zoetis-inc-zts-shares-bought-by-hightower-advisors-llc.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.